Ballantyne, Christie M. and Riegger, Guenter and Moore, Nicholas and Saia, Francesco and Serruys, Patrick W. J. C. (2004) Fluvastatin reduces cardiac mortality in patients with coronary heart disease. CARDIOVASCULAR DRUGS AND THERAPY, 18 (1). pp. 67-75. ISSN 0920-3206, 1573-7241
Full text not available from this repository. (Request a copy)Abstract
Purpose: To test the effectiveness of fluvastatin, 40-80 mg, in reducing the occurrence of cardiac and all-cause mortality in patients with coronary heart disease (CHD). Methods: Meta-analysis of all clinical trials that assessed the effects of fluvastatin in CHD patients on major adverse cardiac events (MACE) as a prespecified endpoint was performed. A pooled analysis of four studies (n = 3525) was performed on an intent-to-treat basis. Clinical end-points were the incidence, and time to first occurrence, of MACE (cardiac death, nonfatal MI, revascularization), noncardiac death, or all-cause death. Lipid parameters were also analyzed. Results: Fluvastatin treatment significantly prolonged the time to cardiac death (p = 0.0174) and the time to cardiac death or nonfatal MI (p = 0.0055) compared with placebo. Fluvastatin significantly reduced the risk of any MACE (Cox risk ratio [RR], 0.85; 95% confidence interval [CI], 0.73-0.98), cardiac death (RR, 0.53; 95% CI, 0.31-0.90), cardiac death or MI (RR, 0.66; 95% CI, 0.49-0.89), all-cause death (RR, 0.65; 95% CI, 0.45-0.94) and all-cause death or MI (RR, 0.69; 95% CI, 0.53-0.90). Fluvastatin significantly lowered total cholesterol and low-density lipoprotein cholesterol levels and was well tolerated, with no cases of rhabdomyolysis in any of the studies assessed in the meta-analysis. Conclusions: This meta-analysis demonstrates clear beneficial effects of fluvastatin on cardiac and all-cause mortality in CHD patients, and supports the use of fluvastatin to reduce the incidence of MACE in a wide range of at-risk patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | RANDOMIZED CONTROLLED-TRIAL; COA REDUCTASE INHIBITORS; PLACEBO-CONTROLLED TRIAL; ARTERY-DISEASE; ANGIOGRAPHIC RESTENOSIS; HYPERTENSIVE PATIENTS; BALLOON ANGIOPLASTY; CHOLESTEROL LEVELS; EXTENDED-RELEASE; PRAVASTATIN; atherosclerosis; cholesterol; coronary disease; meta-analysis; statin |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 03 Aug 2021 11:53 |
| Last Modified: | 03 Aug 2021 11:53 |
| URI: | https://pred.uni-regensburg.de/id/eprint/38125 |
Actions (login required)
 |
View Item |
